|
LZIC expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.78239670087532E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.50970413526875E-11 |
| Normal-vs-Stage2 |
4.350600E-04 |
| Normal-vs-Stage3 |
8.22940049438614E-10 |
| Normal-vs-Stage4 |
7.63009655457836E-11 |
| Stage1-vs-Stage2 |
1.622400E-01 |
| Stage1-vs-Stage3 |
3.476600E-01 |
| Stage1-vs-Stage4 |
1.663750E-02 |
| Stage2-vs-Stage3 |
6.672300E-02 |
| Stage2-vs-Stage4 |
6.323200E-03 |
| Stage3-vs-Stage4 |
2.134000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.59912100122983E-12 |
| Normal-vs-AfricanAmerican |
1.203620E-03 |
| Normal-vs-Asian |
1.23309999988663E-08 |
| Caucasian-vs-AfricanAmerican |
3.167200E-01 |
| Caucasian-vs-Asian |
5.359000E-01 |
| AfricanAmerican-vs-Asian |
1.683780E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.54576351718561E-12 |
| Normal-vs-Female |
2.48839948646662E-10 |
| Male-vs-Female |
2.123600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.38550001974147E-09 |
| Normal-vs-Age(41-60Yrs) |
1.4021994676483E-10 |
| Normal-vs-Age(61-80Yrs) |
9.14279996155898E-09 |
| Normal-vs-Age(81-100Yrs) |
7.845500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.383200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.696600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.321400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.264400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.426800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.225400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.060500E-02 |
| Classical-VS-Follicular |
3.797200E-01 |
| Classical-VS-Other |
1.898800E-01 |
| Classical-VS-Normal |
3.42740280601106E-11 |
| Tall-VS-Follicular |
1.063980E-02 |
| Tall-VS-Other |
7.253600E-01 |
| Tall-VS-Normal |
9.14930020634586E-10 |
| Follicular-VS-Other |
1.704610E-01 |
| Follicular-VS-Normal |
1.67436999999326E-05 |
| Other-VS-Normal |
7.412100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.23300003330007E-09 |
| Normal-vs-N1 |
4.13450385039482E-11 |
| N0-vs-N1 |
7.499600E-03 |
|
|
